Mapi Pharma

Executive Summary

Mapi Pharma is an Israeli clinical-stage biotechnology company focused on developing long-acting depot injectable formulations and complex active pharmaceutical ingredients (APIs). Its lead candidate, a once-monthly Glatiramer Acetate depot (GA Depot), aims to improve treatment adherence for multiple sclerosis (MS) patients by reducing injection frequency. The company also develops extended-release generic versions of existing drugs and novel peptide therapeutics, addressing underserved neurological and psychiatric conditions. With over 15 years of experience and a dedicated manufacturing facility, Mapi Pharma differentiates itself through proprietary polymeric microsphere technology that enables sustained drug release over weeks to months. Currently, the company is advancing GA Depot through Phase 3 clinical trials, with top-line data expected in the coming quarters. Given the large MS market and the potential for reduced dosing frequency, positive results could lead to regulatory filings and strategic partnerships. Additionally, Mapi's pipeline includes early-stage programs in pain and epilepsy, providing further upside. The private nature of the company limits public disclosures, but its progress to late-stage development suggests meaningful value creation. Key upcoming catalysts include Phase 3 data readout for GA Depot, potential regulatory submissions, and visibility into additional pipeline assets.

Upcoming Catalysts (preview)

• H2 2026Phase 3 Top-Line Data for Once-Monthly Glatiramer Acetate Depot70% success
• Q1 2027Regulatory Submission (FDA/EMA) for GA Depot50% success
• Q4 2026Pipeline Expansion or Partnership Announcement40% success